Abstracts tagged "antibodies and systemic sclerosis"

Abstract Number: 730 • 2017 ACR/ARHP Annual Meeting
The Association of Pulmonary Hypertension with Isolated Nucleolar Serum Autoantibodies in Systemic Sclerosis
Kathleen Aren¹, Mary A. Carns¹, Michael Cuttica², Julia (Jungwha) Lee³, Virginia D. Steen⁴ and Monique Hinchcliff⁵, ¹Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²Northwestern University, Feinberg School of Medicine, Division of Pulmonary and Critical Care, Chicago, IL, ³Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁵Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Serum antibodies are used to identify SSc patients who may be at higher risk for SSc-PH. The Pulmonary Hypertension Assessment and Recognition of Outcomes…
Abstract Number: 2918 • 2016 ACR/ARHP Annual Meeting
The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Ashraf Raslan¹, Clifford Stermer² and Vivien Hsu³, ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Medicine, Rutgers-RWJMS, New York, NY, ³Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Antinuclear antibody (ANA) test is positive in nearly 95% of patients with systemic sclerosis (SSc) [1]. We aim to identify the clinical relevance of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].